REG - Hutchmed China Ltd - Appointment of Independent Non-executive Director

HUTCHMED (China)Announcement

Tue 09:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251014:nRSN1774Da&default-theme=true

RNS Number : 1774D  Hutchmed (China) Limited  14 October 2025

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

 

 

Hong Kong, Shanghai & Florham Park, NJ - Tuesday, October 14, 2025:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) " or the
"Company") (Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Tan Shao
Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive
Director and a member of the Technical Committee of the Company with effect
from October 15, 2025.

 

Professor Tan, aged 47, has over 20 years of experience in oncology, with his
main research interests focusing on thoracic, head and neck malignancies, and
drug development. He is the head of the Division of Clinical Trials and
Epidemiological Sciences and a senior consultant in the Division of Medical
Oncology at the National Cancer Centre Singapore ("NCCS"). He is a professor
at Duke-NUS Medical School and serves as a senior clinician-scientist at the
Genome Institute of Singapore.

 

Dr Dan Eldar, Chairman of HUTCHMED, said "On behalf of the Board, I would like
to extend a warm welcome to Professor Tan. Professor Tan has a proven track
record in early phase clinical trials of novel therapeutics, and we believe
that his expertise in targeted therapies, biomarker development and clinical
oncology will strongly support the strategic growth of the Company and drive
continued innovation in cancer drug development."

 

Professor Tan currently leads the Experimental Cancer Therapeutics Unit (ECRU)
at the NCCS, one of Asia's largest Phase I units, which runs approximately
30-40 trials at any time. He is also the Principal Investigator of the Cancer
Therapeutics Research Laboratory at NCCS focused on developing representative
patient-derived preclinical models to study drug response and resistance,
complementing his leadership in multiple biomarker-driven early-phase and
first-in-human clinical trials. He currently serves as the principal
investigator of the National Medical Research Council ("NMRC") Lung Cancer
Large Collaborative Grant in Singapore (2025-2029 and previously 2019-2023)
and chairs the Asian Thoracic Oncology Research Group, a regional platform for
translational research and clinical trials.

 

Professor Tan's research focuses on applying "omics" technologies to
understand drug resistance and accelerate the development of novel therapies
and biomarkers. His work has earned numerous accolades, including the
International Association for the Study of Lung Cancer (IASLC) Daniel C. Idhe
Lectureship Award for Medical Oncology, the American Society of Clinical
Oncology (ASCO) Young Investigator Award, and the SingHealth Group Chief
Executive Officer Outstanding Clinician-Researcher Award. He is a three-time
recipient of the NMRC Clinician-Scientist Award.

 

He has published extensively, contributing to over 200 peer-reviewed articles
including those in leading journals such as Nature, Nature Medicine, New
England Journal of Medicine, and The Lancet Oncology. Professor Tan has held
leadership roles in global oncology forums, including Chair of the IASLC
Education Committee and Co-Chair of the World Conference on Lung Cancer
(WCLC). He currently serves as Associate Editor for the Journal of Thoracic
Oncology, Scientific Editor for Cancer Discovery and Senior Editor for
Clinical Cancer Research. He is a member of the American Association of Cancer
Research (AACR), ASCO, the European Society for Medical Oncology (ESMO), IASLC
and the Singapore Society of Oncology of which he was also a past secretary.

 

Professor Tan holds a Bachelor of Science degree with first class honors in
tumor biology from University College London, University of London; a Bachelor
of Medicine and Bachelor of Surgery from St Bartholomew's and the Royal London
School of Medicine and Dentistry; and a PhD from the National University of
Singapore. He is a member of the Royal College of Physicians of the United
Kingdom.

 

Additional Disclosure Pursuant to the AІM Rules for Companies and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("HK Listing Rules")

Professor Tan is currently a director of Epoch Biosciences Pte. Ltd. Save for
this appointment, Professor Tan has held no other directorships or
partnerships during the period of five years prior to his appointment as a
director of HUTCHMED. He does not have any relationship with any Directors,
senior management or substantial or controlling shareholders of HUTCHMED.
Professor Tan has confirmed (a) his independence as regards each of the
factors for independence referred to in Rule 3.13(1) to (8) of the HK Listing
Rules; (b) that he had no past or present financial or other interest in the
business of the Company or its subsidiaries or any connection with any core
connected person (as defined in the HK Listing Rules) of the Company; and (c)
that there are no other factors that may affect his independence at the time
of his appointment.

 

The initial term of the appointment of Professor Tan as an Independent
Non-executive Director of the Company shall end at the next following annual
general meeting of the Company, subject to retirement in accordance with the
Articles of Association of the Company and applicable legal and regulatory
requirements, and thereafter for successive periods of 12 months, unless he is
not re-elected at the next following annual general meeting or his appointment
is otherwise terminated earlier by either party in writing. The director's
fees of Professor Tan as an Independent Non-executive Director and member of
the Technical Committee of the Company under his appointment letter are
US$76,000 and US$8,000 per annum respectively, which were determined by the
Board with reference to the director's duties and responsibilities and
prevailing market conditions. Such fees are subject to review from time to
time and proration for any incomplete year of service.

 

Professor Tan does not have any interest in any shares of the Company within
the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of
the Laws of Hong Kong).

 

Save for the information disclosed above, there is no other information in
relation to Professor Tan that is required to be disclosed pursuant to Rule 17
and Schedule 2(g) of the AІM Rules for Companies or Rule 13.51(2) of the HK
Listing Rules, and there are no other matters concerning the appointment of
Professor Tan that are required to be brought to the attention of the
shareholders of HUTCHMED.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery, global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception,
HUTCHMED has focused on bringing drug candidates from in-house discovery to
patients around the world, with its first three medicines marketed in China,
the first of which is also approved around the world including in the US,
Europe and Japan. For more information, please visit www.hutch-med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

 

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect HUTCHMED's current
expectations regarding future events. Forward-looking statements involve risks
and uncertainties. Such risks and uncertainties include, among other things,
the risk that current or future appointees to HUTCHMED's board of directors
are not effective in their respective positions, the difficulty in locating
and recruiting suitable candidates for its board of directors and the
management difficulties which may arise from changes in HUTCHMED's board of
directors. Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see HUTCHMED's
filings with the U.S. Securities and Exchange Commission, on AІM and with The
Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to
update or revise the information contained in this announcement, whether as a
result of new information, future events or circumstances or otherwise.

 

 

CONTACTS
 Investor Enquiries                                  +852 2121 8200 / ir@hutch-med.com

 Media Enquiries
 FTI Consulting -                                    +44 20 3727 1030 / HUTCHMED@fticonsulting.com
 Ben Atwell / Alex Shaw                              +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
 Brunswick - Zhou Yi                                 +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

 Panmure Liberum                                     Nominated Advisor and Joint Broker
 Atholl Tweedie / Emma Earl / Rupert Dearden         +44 20 7886 2500

 Cavendish                                           Joint Broker
 Geoff Nash / Nigel Birks                            +44 20 7220 0500

 Deutsche Numis                                      Joint Broker
 Freddie Barnfield / Jeffrey Wong / Duncan Monteith  +44 20 7260 1000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAMZMMGVFRGKZM



            Copyright 2019 Regulatory News Service, all rights reserved